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Sexually transmitted HIV-1 strains utilize the chemokine receptor CCR5 for viral entry and inhibitors targeting this coreceptor offer great
promise for antiretroviral therapy. They also raise the question, however, whether viral variants exhibiting altered coreceptor interactions and
resistance against these antiviral agents might still be pathogenic. In the present study, we analyzed a SIVmac239 envelope (Env) mutant (239DL)
containing two mutations in the V3 loop which reduced viral entry via CCR5 by 10- to 20-fold, disrupted utilization of common alternative SIV
coreceptors and changed the way Env engaged CCR5. To evaluate its replicative capacity and pathogenic potential in vivo we infected six rhesus
macaques with 239DL. We found that 239DL replication was only slightly attenuated early during infection. Thereafter, a D324V change, which
restored efficient CCR5 usage and coincided with 239wt-like levels of viral replication, emerged in two animals. In contrast, the viral geno- and
phenotype remained stable in the other four rhesus macaques. Although these animals had about 100-fold reduced viral RNA loads relative to
239wt-infected macaques, they showed pronounced CD4 T-cell depletion in the intestinal lamina propria, and one developed opportunistic
infections and died with simian AIDS. Thus, changes in the V3 loop that diminished CCR5 usage and altered Env interactions with CCR5 reduced
the pathogenic potential of SIVmac in rhesus macaques but did not abolish it entirely.
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HIV-1 entry is a highly promising target for therapeutic
intervention. The HIV-1 entry inhibitor T-20 (also called
enfuvirtide or Fuzeon) is already used in the clinic (Kilby and
Eron, 2003) and antiviral agents interfering with CD4 or
coreceptor (CCR5 or CXCR4) engagement are currently
evaluated in clinical trials (Markovic, 2006; Moore and
Doms, 2003; Pierson et al., 2004). CCR5 is a particularly
promising drug target because it is used by most primary HIV-1
strains. Moreover, the genetic absence of CCR5 in humans is
associated with significant resistance to virus infection with no
obvious associated immune dysfunctions, suggesting a high
functional redundancy of this chemokine receptor (Berger et al.,
1999). Small molecule inhibitors targeting CCR5 protected
macaques against infection with a hybrid simian/human
immunodeficiency virus (SHIV) (Veazey et al., 2005b; Veazey
et al., 2005a) and reduced the viral loads in SIV infected animals
(Veazey et al., 2003) and in HIV-1 infected patients enrolled in
advanced clinical trials (Kuhmann and Moore, 2004; Pierson et
al., 2004; Pöhlmann and Reeves, 2006). Thus, CCR5 inhibitors
might complement established antiviral regimens in the near
future.
Although entry inhibitors hold great promise, particularly for
the treatment of people who have failed conventional therapy,
there is no doubt that resistance to this new class of
antiretroviral agents will also arise (Briz et al., 2006; Markovic,
2006; Moore and Doms, 2003; Pöhlmann and Reeves, 2006).
The V3 loop of gp120 largely determines HIV-1 coreceptor
choice and a few amino acid changes in this region can mediate
a coreceptor switch from CCR5 to CXCR4. Thus, it was
perhaps predictable that CCR5 inhibitors might select for
CXCR4-tropic HIV-1 V3 loop variants (Mosier et al., 1999). It
was less expected, however, that changes in the V3 loop could
also confer resistance to small molecule CCR5 inhibitors by
altering the gp120/coreceptor interactions rather than by
mediating a coreceptor switch (Kuhmann et al., 2004; Trkola
et al., 2002). A third possibility for resistance development is
the use of alternative coreceptors. Thus, at least twelve
chemokine or orphan receptors other than CCR5 and CXCR4
can support infection by particular HIV strains on indicator cell
lines (Berger et al., 1999; Clapham and McKnight, 2002) and
alternative cofactors might allow replication of some HIV-1
strains in primary T-cells (Cilliers et al., 2005; Willey et al.,
2003). These observations raise the question as to whether
primate lentiviruses that exhibit altered CCR5 engagement or
enter T-cells CCR5 and CXCR4 independently via alternative
coreceptors can spread efficiently in primary cells and cause
disease in vivo.
The SIV/macaque model allows assessment of the replica-
tive capacity and pathogenic potential of primate lentiviruses.
Similarly to HIV-1, primary SIV strains use CCR5 as major
coreceptor (Chen et al., 1997; Kirchhoff et al., 1997; Marcon et
al., 1997). In general, the coreceptor usage profile of SIV is
broader on coreceptor-transfected cell lines (Marx and Chen,
1998) and PBMCs (Zhang et al., 2000) than that of HIV-1. In
contrast to HIV-1, however, SIV usually does not utilizeCXCR4 (Chen et al., 1997; Kirchhoff et al., 1997; Marcon et al.,
1997), albeit exceptions have been described (Picker et al.,
2004). We have previously shown that changes at amino acid
position 324 in the V3 loop of the SIVmac239 molecular clone
can modulate coreceptor interactions and, in some cases, allow
efficient infection of cell lines via unknown alternative
coreceptors (Pöhlmann et al., 2004). Thus, as for HIV-1 Env,
the V3 loop in SIV Env is a major determinant of coreceptor
tropism and engagement (Kirchhoff et al., 1994; Pöhlmann et
al., 2004).
In the present study a mutant of SIVmac239 containing
changes of I324D and P334L (239DL) in the V3-loop was
analyzed both in cell culture systems and in vivo in the SIV/
macaque model. The two mutations altered the gp120/CCR5
interaction, impaired CCR5-mediated entry and eliminated the
ability of SIVmac to utilize established alternative coreceptors.
Despite inefficient utilization of the common SIV coreceptors,
SIVmac 239DL replicated with 239wt-like efficiency in rhesus
macaque PBMCs (rhPBMCs). Spread of 239DL in these cells
might be due to CCR5 usage, since high doses of small
molecule CCR5 inhibitors reduced 239DL infection about 3- to
4-fold. However, the substantial remaining infectivity suggests
that usage of alternative cofactors or entry via CCR5
conformations not affected by the inhibitors tested might also
contribute to 239DL replication. After infection of six rhesus
macaques with SIVmac 239DL, revertants showing efficient
utilization of CCR5 were only observed in two of these animals.
The remaining four monkeys showed lower viral RNA loads
than 239wt-infected animals but developed signs of disease
progression and one animal died with simian AIDS. In
summary, the properties of SIVmac 239DL suggest that
efficient utilization of CCR5 is important but not absolutely
required for the pathogenesis of AIDS.
Results
The 239DL variant exhibits altered CCR5 usage and does not
use known alternative coreceptors for entry
We have previously shown that individual changes at amino
acid position 324 in the V3 loop of the SIVmac239 Env alter
coreceptor usage and, in some cases, allow SIVmac to replicate
efficiently in primary T-cells despite inefficient entry into cell
lines expressing exogenous CCR5 and GPR15 (Pöhlmann et al.,
2004). It remained elusive, however, whether such SIV mutants
are capable to spread efficiently and to cause disease in vivo in
infected rhesus macaques. To address this, we selected a mutant
of SIVmac239 containing substitutions of I324D and P334L in
the V3 loop region for detailed analysis both in vitro and in
vivo. The 239DL mutant virus did not infect CEMx174 and
C8166 cells, which express CD4 together with GPR15 and
CXCR4 (Kirchhoff et al., 1997) and are highly susceptible to
239wt infection (Fig. 1A). In contrast, SIVmac 239DL was
capable to infect the rhesus-derived T-cell line 221–89
(Alexander et al., 1997) and rhPBMCs (Fig. 1A), both
expressing CCR5 and additional chemokine and orphan
receptors. Usually, 239DL infected 221–89 cells and rhPBMC
Fig. 2. Differential interaction of 239wt and 239DL Env proteins with CCR5.
(A) Env-mediated cell–cell fusion. The abilities of 239wt (black bars) and
239DL (white bars) Env expressing effector cells to mediate fusion with the
indicated target cells were quantified 7 hours after mixing effector and target
cells as described in the Methods section. (B) Efficiencies of 239wt and 239DL
Env-mediated cell–cell fusion via the indicated CCR2/CCR5 chimeras.
Chimeras are designated by their extracellular domains as described previously
(Rucker et al., 1996), e.g. in chimera 5552 the N-terminus and the extracellular
loops 1 and 2 are derived from CCR5, while the third extracellular loop
originates from CCR2b. Representative experiments are shown in A and B,
and the results were confirmed in two independent experiments. Error bars
indicate SD.
Fig. 1. Cell tropism and coreceptor usage of the 239DL variant. (A) Cell tropism
of 239DL. The indicated cell lines or primary cells were infected with SIVmac
239wt and 239DL reporter viruses expressing the GFP reporter gene. Infections
were performed with viral stocks containing 30 ng of the p27 antigen.
Percentages of 239DL-infected (GFP+) cells are shown relative to 239wt
(100%). The percentages of cells staining GFP+ after infection with SIVmac
239wt were: 2.8%, CEMx174; 21%, C8166; 5.1%, 221–89; 0,08%, rhPBMC
D1; 0.23%, D2; and 0.25%, D3. D, donor. (B) Coreceptor tropism of 239DL.
293T cells expressing rhCD4 and the indicated rhesus macaque chemokine
receptors or human STRL33, were infected with viral stocks containing 50 ng
p27 antigen of SIVmac 239wt (black bars) and 239DL (white bars) luciferase
reporter viruses. Panels A and B show average values (±SD) derived from
triplicate infections in representative experiments, similar results were obtained
in two independent experiments.
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efficiency varied between PBMCs from different macaques
(example shown in Fig. 1A). Infection of transiently transfected
293T cells confirmed that SIVmac 239DL is unable to utilize
alternative coreceptors such as GPR1, APJ, GPR15 and
STRL33 appreciably, and infects cells overexpressing CD4 in
conjunction with human- or macaque-derived CCR5 with at
least 10-fold reduced efficiency compared to 239wt (Fig. 1B,
and data not shown). As expected from the results of our
previous study (Pöhlmann et al., 2004), the amino acid changes
in the V3 loop did not impair efficient expression, processing
and virion incorporation of the viral Env protein (data not
shown).
Next, we assessed the ability of the 239DL Env to
mediate cell–cell fusion. Although SIVmac 239DL was
generally substantially less infectious than 239wt (Fig. 1), the
239DL Env was even more effective than that of 239wt in
mediating CCR5-dependent cell–cell fusion, particularly in
the absence of CD4 (Fig. 2A). However, 239DL did not
infect 293T cells expressing CCR5 to appreciable levels in
the absence of CD4 (data not shown). To further explore the
interaction of 239DL with CCR5, we investigated its ability
to use chimeric CCR5 and CCR2b molecules (Rucker et al.,
1996) for fusion. Our results showed that the presence of the
second extracellular loop of CCR5 in the chimeric molecules
is sufficient for efficient 239wt Env- but not 239DL Env-
mediated cell–cell fusion (Fig. 2B). Additionally, replacing
the N-terminus or the first and third extracellular loops of
CCR5 by the corresponding regions of CCR2b had a greater
impact on 239DL Env-mediated fusion compared to 239wt.
Thus, unlike the 239wt Env the 239DL gp120 requiredmultiple extracellular domains of CCR5 to mediate efficient
cell–cell fusion.
The small molecule CCR5 inhibitor TAK-779 does not block
239DL infection of rhPBMCs
We next investigated whether the altered interaction of the
239DL Env with CCR5 affects its sensitivity to TAK-779, a
small molecule CCR5 inhibitor, that blocks CCR5-tropic HIV-1
and SIVmac infection (Dragic et al., 2000; Igarashi et al., 2003;
Zhang et al., 2000). Infection and cell–cell fusion experiments
showed increased susceptibility of the 239DL Env to TAK-779
inhibition compared to 239wt Env, independently if human or
rhesus CCR5 was used (Fig. 3A top panel, and data not shown).
Similarly, the modified natural CCR5 ligand NNY-RANTES
also blocked infection of P4-CCR5 cells (which express human
CD4 and CCR5, Charneau et al., 1994) by the 239DL mutant
virus more efficiently than 239wt (Fig. 3B), whereas both
viruses were equally susceptible to inhibition by T20, which
targets the gp41 region (Fig. 3B). A different phenotype,
however, was observed in rhPBMC and the rhesus macaque-
Fig. 3. Effect of entry inhibitors on SIVmac 239DL infection. (A) Inhibition of 239wt and 239DL infection by TAK-779 (top panel) and PSC-RANTES (bottom
panel). Cells were incubated with the indicated concentrations of inhibitor prior to infection. Infection of 221–89 and rhPBMCs was quantified by measuring the
percentages of infected GFP+ cells, while infection of Magi R5 cells was quantified by measuring β-galactosidase activity in cell lysates. (B) Inhibition of 239wt and
239DL infection of P4-CCR5 indicator cells by NNY-RANTES and the fusion inhibitor T20. Results in all panels are presented relative to 239wt and 239DL activity in
the absence of inhibitor, which was set as 100%, and represent averages (±SD) derived from representative experiments performed in duplicates or triplicates. The
results are representative for two to four independent experiments.
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completely blocked SIVmac 239wt infection of rhPBMCs and
221–89 cells, whereas 239DL infection was only reduced by 3-
to 4-fold (Fig. 3A, top panel). These findings are compatible
with the idea that 239DL entry into 221–89 cells and rhPBMC
might be mediated by CCR5 and an alternative coreceptor,
while 239wt exclusively uses CCR5 and is thus highly sensitive
to TAK-779. However, PSC-RANTES, another inhibitory
RANTES derivative, did not appreciably block 239wt and
239DL infection of 221–89 cells despite preventing entry into
CCR5-transfected cells with high efficiency (Fig. 3A, bottom
panel), making it questionable whether 239wt infects 221–89
cells in a CCR5-dependent manner. Thus, the mechanisms
governing 239wt and 239DL resistance to CCR5 inhibitors inthe context of 221–89 cells and rhPBMCs seem to be complex
and might involve both, entry via one or more alternative
cofactors and usage of CCR5 conformational variants with
differential sensitivity to TAK-779 and PSC-RANTES.
The 239DL variant exhibits an altered cell tropism relative to
239wt
It has been reported that some changes in the HIV-1 V3 loop
reduce the efficiency of CCR5-mediated infection of indicator cell
lines but not the efficiency of viral replication in human PBMC
(Trkola et al., 2002). To assess whether 239DL shows similar
propertieswe examined its in vitro replicative capacity. Consistent
with its inability to utilize GPR15 efficiently for infection (Fig. 1),
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but not CCR5 (Kirchhoff et al., 1997) (Fig. 4A). The mutant virus
was also unable to spread in PM-1 cells (Fig. 4B), which express
CCR5 (Lusso et al., 1995) but at substantially lower levels than
primary T-cells. In contrast, the 239DL variant replicated with
239wt-like efficiency in 221–89 cells and in rhPBMC (Figs. 4C,
D). The mutant virus was also capable of replicating in PBMC
derived from human blood donors, albeit with substantially
delayed kinetics compared to 239wt (Fig. 4E). Lack of
appreciable infection of PBMCs derived from two individuals
homozygous for theΔ32-ccr5 deletion (Liu et al., 1996; Samson
et al., 1996) demonstrated that replication of 239DL in human-
derived PBMCs was CCR5-dependent (Fig. 4F). In contrast,
239wt was able to replicate efficiently in CCR5-negative
huPBMC, which is in agreement with its ability to utilize
alternative entry cofactors such as human GPR15 and STRL33
(Deng et al., 1997; Farzan et al., 1997).
The 239DL variant is only moderately attenuated in vivo
Alteration of CCR5 usage instead of a switch to CXCR4
might be the preferred way of HIV-1 to acquire resistance
against CCR5 inhibitors, at least in cell culture (Kuhmann et al.,
2004; Marozsan et al., 2005; Trkola et al., 2002). Adaptation to
entry into T-cells via alternative cofactors might be an other
possibility to acquire resistance, and evidence that some
primary HIV-1 isolates can use such receptors for efficient
replication in T-cells has been reported (Cilliers et al., 2005;
Willey et al., 2003). The emergence of viral variants with altered
CCR5 interactions or extended coreceptor use might potentially
complicate therapeutic strategies aiming to block the two majorFig. 4. Replicative capacity of SIVmac 239DL in vitro. The (A) CEMx174, (B) PM-
and (E, F) human donors were infected with SIVmac 239wt (▪) and the 239DL varia
Similar results were obtained using independent virus stocks, higher viral doses (up
simian donors, respectively, including another human donor with the ccr5 Δ32/Δ32HIV-1 coreceptors. Thus, it is of interest to determine whether
such viruses show a virulent or attenuated phenotype in vivo.
We assessed the replicative capacity and pathogenicity of
239DL in vivo by inoculating six rhesus macaques with the
mutant virus. All animals became productively infected. Early
during infection three of the rhesus macaques showed viral
RNA loads similar to 239wt-infected animals, whereas the viral
loads were about 10-fold lower in the remaining macaques (Fig.
5A, left). On average, the peak virus loads during acute
infection were 2.5-fold lower compared to 239wt, but 25-fold
higher (P=0.0053) than those obtained after infection with
attenuated nef-deleted SIVmac239 ΔNU (Fig. 5A, right). Thus,
replication of SIVmac 239DL in rhesus macaques was only
slightly attenuated early during infection. However, only two of
the six 239DL-infected animals (Mm9547, Mm9548) main-
tained high plasma RNA loads during later stages of infection
(Fig. 5B, left).
Next, we investigated whether the high viral loads in animals
Mm9547 and Mm9548 were associated with the emergence of
revertant viruses. To assess this, we measured viral replication
in cocultures of PBMCs derived from these two animals with
CEMx174 cells. This cell line expresses GPR15 but not CCR5
and supports replication of 239wt but not of 239DL (Fig. 4A).
Thus, efficient viral spread in these cocultures indicates the
presence of SIVmac variants containing reversions or compen-
satory changes in their Env glycoproteins allowing effective
utilization of GPR15. Indeed, efficient viral replication was
observed in these cocultures and analysis of proviral sequences
in rhPBMCs confirmed the emergence of SIVmac variants
containing a change of D324V in the V3 region by 4 to 6 weeks
post-infection (wpi; Mm9547 and Mm9548). Functional1 and (C) 221–89 cell lines and prestimulated PBMCs derived from (D) simian
nt (▴). Infections were performed with virus stocks containing 5 ng p27 antigen.
to 100 ng p27 antigen), and PBMCs derived from 4 to 6 different human and
genotype. PSL: photon-stimulated light emission.
Fig. 5. Replication of the SIVmac 239DL variant in rhesus macaques. Six
animals (▴, Mm9539; ♦, Mm9547;●, Mm9548;▵, Mm10008;⋄, Mm10009;
○, Mm10010) were infected by intravenous inoculation of medium containing
5 ng of p27 antigen. (A) Levels of viral RNA load during acute infection. The
bars indicate average values±SEM. For comparison, data obtained from
SIVmac239 wild-type (239wt) and nef deleted (ΔNU)-infected animals are also
indicated. (B) Levels of viral RNAwere measured over the course of 36 weeks.
The right panel indicates the average viral RNA levels±SEM measured at 12,
20, 28 and 36 wpi in the four 239DL-infected macaques, in which no reversions
were observed, and in the two animals where SIVmac variants containing a
D324V substitution (239-(V)L) emerged by 4 to 6 wpi. For comparison, RNA
levels in 239wt or ΔNU infected animals are also shown.
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restore efficient utilization of CCR5, GPR15 and STRL33
coreceptors and hence resulted in a 239wt-like phenotype
(Pöhlmann et al., 2004). In contrast, no revertant viruses could
be reisolated at any time from the four animals with lower viral
loads. Notably, this was not just due to lower numbers of SIV-
infected PBMC. In fact, virus isolation was only negative
throughout the investigation period when CEMx174 and PM1
cells were used for cocultivation. In contrast, the 239DL mutant
virus could be reisolated using PBMC from uninfected rhesus
macaques as target cells, albeit with relatively low efficiency.
Further analysis showed that virus recovered from these four
animals was poorly infectious and did not replicate to detectable
levels on CEMx174 and PM1 cells. In agreement with this viral
phenotype, sequence analysis of genomic DNA from rhPBMCs
and from plasma virus obtained from these four animals showed
that the 239DL mutations did not revert and that no potentially
compensatory changes were selected in the env gene (approxi-
mately 200 bp up- and downstream of the V3 region were
analyzed, data not shown). In the absence of the D324V changethe average RNA levels declined more than 400-fold from peak
levels of 6.4×106 to 4.7×106 copies/ml during acute infection
to 1.5×104 to 1.3×104 at 28 wpi (Fig. 5B, left). Thus,
replication of the 239DL variants during later stages of infection
was strongly attenuated, similarly to nef-deleted SIV infection
(Fig. 5B, right). Notably, the emergence of the D324V
substitution was associated with about 100-fold higher plasma
viral RNA loads (P=0.0055; Fig. 5B, right). Thus, despite
normal replication in vitro in rhPBMC (Fig. 4D), 239DL
replication in the peripheral blood of rhesus macaques was
strongly attenuated later during infection.
The 239DL variant depletes T-cells in the intestine and can
cause immunodeficiency
All six 239DL-infected animals maintained relatively
stable percentages of CD4+ and CD4+/CD29+ T-cells in
peripheral blood during the first 12 wpi (Figs. 6A, D).
However, animals Mm9547 and Mm9548 in which the
D324V revertant emerged as well as one additional rhesus
macaque (Mm9539) showed a marked depletion of CD4+ T-
cells in the intestine (Fig. 6B), a major site of viral replication
and T-cell depletion (Kewenig et al., 1999; Schneider et al.,
1995; Veazey et al., 1998). The two animals (Mm9547 and
Mm9548) with high viral loads developed simian AIDS.
Mm9548 developed moderate lymphadenopathy and spleno-
megaly by 4 wpi and showed opportunistic infections of the
gastrointestinal tract (Giardia sp., Entamoeba sp.). This
animal died at 42 wpi because of severe disease. Histopatho-
logic examination revealed SIV-associated lymphoid hyper-
plasia of multiple other organs, including lymph nodes, spleen
and gastrointestinal tract and severe lung disease associated
with Klebsiella pneumonia. Mm9547 showed a more
protracted clinical course of infection. Postmortem examina-
tion of euthanasia at 93 wpi revealed generalized moderate
lymphatic hyperplasia and Pneumocystis carinii pneumonia.
Disease progression in these two 239DL-infected animals
could be expected because of the selection of the D324V
change, which restored efficient utilization of CCR5 and
alternative coreceptors and was associated with the develop-
ment of high viral loads (Fig. 5). Less predictively, Mm9539
progressed to fatal immunodeficiency by 62 wpi in the
absence of detectable revertants and despite about two logs
reduced viral RNA levels compared to typical 239wt-infected
animals. Histopathologic examination revealed opportunistic
infections (Giardia, Trichomonas, Staphylococcus) in multiple
organs, an erosive, chronically active gastroenteritis and a
nonbacterial thrombotic endocarditis. In contrast, the remain-
ing three animals showed only mild clinical alterations such
as minor to moderate lymphadenopathy, but exhibited
profound depletion of intestinal CD69+, CD29+ and HLA-
DR+, CD4+ T-cells (Fig. 6, and data not shown). Sequence
analysis of env fragments amplified directly from intestinal
tissue revealed that no revertants emerged in Mm9539,
Mm10008, Mm10009, and Mm10010, thus confirming that
the T-cell depletion in the intestine was indeed due to 239DL
replication. Thus, the 239DL mutant virus was clearly less
Fig. 6. Loss of CD4+ T cells in rhesus macaques infected with the SIVmac 239DL variant. The percentages of total CD4+ T-cells and of CD4+/CD29+ T-cells in
peripheral blood (A, D) and in colon (B, E) of the six 239DL infected macaques (▴, Mm9539; ♦, Mm9547;●, Mm9548;▵, Mm10008;⋄, Mm10009;○, Mm10010)
are shown. Panels C and F indicate average values (±SD) for the four macaques infected with SIVmac 239DL not showing geno- or phenotypic reversions their env
genes (▪, colon;□, periphery) and average values for the two macaques (9547, 9548) in which efficient entry was restored by 4 and 6 wpi, respectively (♦, colon;⋄,
periphery).
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CD4+ memory T-cell in the gastrointestinal tract and fatal
disease in one animal.
Discussion
In the present study we show that two amino acid changes in
the V3 loop of SIVmac239 impair efficient utilization of the
major SIV coreceptor CCR5 and disrupt the ability to utilize
established alternative coreceptors for viral entry (Fig. 1).
However, these substitutions did not impair efficient viral
replication in primary rhesus T-cells (Fig. 4). Inhibition of
239wt and 239DL infection by CCR5 inhibitors was dependent
on the cellular background and, in case of 239wt, the inhibitor
used (Fig. 3). The mechanisms governing resistance are unclear.
For 239DL we assume that entry into T-cells is to 60–70%
mediated by inhibitor-sensitive CCR5 and usage of this receptor
might support viral spread in vitro and in vivo. The remaining
entry activity might in turn be due to efficient use of one or
several alternative coreceptor(s) expressed on rhesus T-cells, or
to usage of CCR5 conformational variants on T-cells, which are
insensitive to certain small molecule inhibitors. Importantly, the
239DL virus replicated almost as efficiently as 239wt in rhesus
macaques during the early phase of infection (Fig. 5A).
Thereafter, the viral RNA loads dropped to levels about 100-
fold lower than those typically observed in 239wt infection in
the four 239DL infected animals showing a stable viral geno-
and phenotype (Fig. 5B). Despite relatively low viral loads,
however, these four macaques exhibited a strong CD4 T-cell
depletion in the lamina propria of the gastrointestinal tract, a key
compartment of HIV/SIV pathogenesis (Brenchley et al., 2004;Kewenig et al., 1999; Mattapallil et al., 2005; Mehandru et al.,
2004; Schneider et al., 1995; Veazey et al., 1998), and one of
them progressed to simian AIDS in the absence of reversions.
These findings might not directly apply to HIV-1 infected
humans since SIVmac uses alternative coreceptors more
commonly than HIV-1 and because rhesus macaques are
known to be particularly susceptible to SIV-induced disease.
Nevertheless, our results provide first evidence that primate
lentiviral replication in the absence of efficient CCR5 usage
might not be entirely apathogenic.
Inhibition of 239DL entry by small molecule CCR5
inhibitors was cell-type-dependent (Fig. 3). 239DL Env-driven
infection was susceptible to inhibition by TAK-779 and
RANTES derivatives in cellular systems in which CCR5 was
the only coreceptor available, while these compounds had only
a moderate effect on infection of cells that express a variety of
coreceptors, suggesting that resistance might be due to usage of
alternative coreceptors (Fig. 3). Several recent reports indeed
suggest that SIV and HIV-1 can infect primary cells via
unidentified cofactors (Cilliers et al., 2005; Forte et al., 2003;
Willey et al., 2003) and we demonstrated that substitutions of
amino acid 324 can confer engagement of such receptors
(Pöhlmann et al., 2004); the identification of the coreceptors
used by SIVmac for CCR5-independent entry into primary cells
is therefore an important task. In this regard it is noteworthy that
TAK-779 but not the RANTES derivative AOP-RANTES
efficiently inhibits viral entry via CCR2b (Zhang et al., 2000),
which is the major coreceptor for SIV from red capped
mangabeys (Chen et al., 1998). Whether inhibition of CCR2b
or other so far unknown coreceptors is involved in the resistance
phenomena observed within this study, particularly in the
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discussed below, remains to be determined.
An alternative mechanism that could account for resistance
to CCR5 inhibitors is engagement of conformational variants
of CCR5. This possibility is supported by the observation that
inhibition of 239wt was cell-type- and inhibitor-dependent.
Thus, 239wt infection of CCR5-transfected cells was
efficiently blocked by TAK-779 and PSC-RANTES, while
only TAK-779 blocked SIVmac entry into the macaque T-cell
line 221–89 (Fig. 3), indicating that these cells might express
CCR5 conformations which are differentially affected by
small molecular inhibitors and which are not present on
transfected cells. In fact, the CCR5 and CXCR4 coreceptors
have been shown to exhibit conformational heterogeneity
(Baribaud et al., 2001; Lee et al., 1999) and differential
posttranslational modification of CCR5, such as sulfonation of
tyrosines in the receptor N-terminus (Choe et al., 2003), might
contribute to conformational heterogeneity of the receptor.
This speculation has also been put forward by Kuhmann et al.
(2004) who investigated how a HIV-1 isolate acquired
resistance to a CCR5 inhibitor during viral spread in
huPBMCs. The resistant variant, which like 239DL used
CCR5 less efficiently for entry into cells lines but replicated in
huPBMCs with wt efficiency, continued to use CCR5 for
entry in the presence of drug (Trkola et al., 2002). Resistance
was due to four amino acid changes in the V3-region, which
altered the interaction with CCR5 (Kuhmann et al., 2004), but
no evidence for a role of alternative coreceptors in the
emergence of viral resistance has been reported. This variant
might therefore have evolved a way of functionally interacting
with CCR5 conformations which are either not recognized or
not perturbed by the inhibitor.
The 239DL mutant virus replicated almost as efficiently as
239wt early during infection of rhesus macaques but, in the
absence of a restorative D324V change, the levels of viral RNA
later during infection were reduced by about two orders of
magnitude (Fig. 5). It remains to be clarified why the 239DL
variant was more “fit” during acute infection. One possible
explanation is that an unknown coreceptor potentially used by
the 239DL mutant virus is more efficiently expressed during
acute infection when the levels of immune activation are
particularly high. Alternatively, similarly to other SIVmac239
V3 Env variants (Means et al., 2001), 239DL might be more
efficiently controlled by the antiviral immune response. A
single-point mutation of D324Vobserved in two of the infected
animals resulted in 239wt levels of viral replication in vivo and
functional analysis in in vitro systems demonstrated that this
change was sufficient to restore efficient utilization of CCR5,
GPR15 and human STRL33. Since the I324D mutation clearly
reduced viral fitness in vivo it is surprising that it remained
stable in four of the six infected rhesus macaques. Moreover, the
phenotypic analysis of viruses isolated from these animals
showed that no compensatory changes were selected elsewhere
in the viral genome. In the other two 239DL-infected rhesus
macaques the restorative D324V change was observed just after
the acute phase of infection when the bulk of viral replication
takes place. Our results suggest that mutations in the primatelentiviral genome reducing viral fitness might be more stable in
vivo than previously anticipated.
Our observations have some implications for the develop-
ment of HIV inhibitors. Firstly, our results suggest that a single
I324D change in the V3 loop region was sufficient to largely
disrupt the ability of SIVmac239 to utilize CCR5 and
alternative entry cofactors and to alter the way Env engages
CCR5, but still allowed significant levels of replication both in
vitro and in vivo. The Env interaction with CCR5 might thus be
quite flexible and changes that severely affect the way these
proteins interact might be compatible with substantial viral
spread in infected patients. Secondly, the 239DL variant was
unable to appreciably infect transformed indicator cell lines,
such as CEMx174 and C8166, commonly used to propagate
SIVmac239. Moreover, infection of cell lines expressing high
levels of exogenous CCR5 was highly sensitive to inhibition by
TAK-779, although 239DL infection of primary rhesus T-cells
was not efficiently blocked by this small molecule CCR5
inhibitor (Fig. 3). Thus, the analysis of possible viral resistance
against coreceptor inhibitors should be performed on primary T-
cells. Thirdly, although the 239DL variant was clearly less fit
than 239wt it still caused significant depletion of specific T-cell
subsets in the GALTwithout significant effects in the periphery.
The GALTcontains most of the lymphatic tissue in the body and
has been identified as a major site of viral replication and T-cell
depletion (Brenchley et al., 2004; Mehandru et al., 2004;
Veazey et al., 1998). Since most studies on the efficacy of HIV-1
inhibitors focus on peripheral blood and lymph nodes, the
development of severe defects in the mucosal immune system
might be missed. In one of the macaques studied here, fatal
immunodeficiency occurred in the absence of revertants and
despite low virus loads. However, there was a profound
depletion of intestinal T-cells in this animal. Such cases might
be rare, but prove that even under conditions when standard
measures of virus replication show a diminished infection, virus
replication in the GALT or other lymphatic tissues may lead to
disease progression in some infected macaques and perhaps also
in some HIV-1-infected humans.
Materials and methods
Cell culture
The adherent cell lines QT6, 293T and P4-CCR5 (Charneau
et al., 1994) were grown in Dulbecco's modified Eagle medium
while the suspension cell lines CEMx174, PM1, 221–89, and
C8166 cells were cultured in RPMI 1640 medium; both media
were supplemented with 10% fetal bovine serum (FBS) and
antibiotics, with the exception of the Herpesvirus saimiri
transformed T-cell line 221–89 (Alexander et al., 1997), which
was maintained in medium supplemented with 100 U/ml
interleukin 2 (IL-2; Boehringer, Heidelberg, Germany), 20%
FBS and antibiotics. PBMCs from human or macaque donors
were isolated from whole blood by Ficoll density gradient
centrifugation. Freshly isolated PBMCs were maintained in
stimulation medium (RPMI 1640 supplemented with 10% FBS,
antibiotics, 100 U/ml IL-2 and 5 μg/ml phytohemagglutinin
283S. Pöhlmann et al. / Virology 360 (2007) 275–285(PHA)) for 3 days. Subsequently, the cells were washed with
medium and cultivated in RPMI 1640 medium supplemented
with 10% FBS, antibiotics and 100 U/ml IL-2 at a density of
1×106 cells/ml. Human blood donors homozygous for a Δ32
deletion in the ccr5 gene (Dean et al., 1996; Rucker et al., 1996;
Samson et al., 1996) were identified by PCR analysis of
genomic DNA as described (Liu et al., 1996).
Mutant construction, virus production and quantification of
virus replication in cell culture
I324D and P334L mutations were inserted into SIVmac239
Env as described previously (Pöhlmann et al., 2004), except that
different internal primers were used for PCR amplification.
Virus stocks were generated as described (Kirchhoff et al.,
1997; Pöhlmann et al., 2004). In brief, 293T cells were calcium
phosphate-transfected with plasmid encoding the proviral
genomes of 239 and 239DL. The culture medium was changed
at 16 h posttransfection and harvested 48 h posttransfection. The
cellular supernatants were passed through 0.4 μm pore size
filters, aliquoted and stored at −80 °C. The content of the viral
p27 capsid antigen in the processed supernatants was
determined employing antigen capture ELISA as previously
described (Pöhlmann et al., 2004). 221–89 (Alexander et al.,
1997) was maintained in the presence of 100 U/ml IL-2 and
20% FCS. PBMC were isolated, cultured and infected as
described elsewhere (Pöhlmann et al., 2004). Viral spread in
infected cell lines and PBMC was analyzed by determining
reverse transcriptase (RT) activity in culture supernatants as
previously described (Potts, 1990). In brief, aliquots of
supernatants from infected and control cultures were taken at
regular intervals and stored at −80 °C. Subsequently, the
supernatants were thawed in parallel, 5 μl supernatant per
sample was transferred into 96-well plates and 25 μl of RT mix
was added per well (RT mix contains: 50 mM Tris pH 7.8,
75 mM KCl, 2 mM dithiothreitol, 4.95 mM MgCl2, 5 μg/ml
polyadenylic acid (Pharmacia, Sweden), 1.575 μg/ml pd(t) 12–
18 (Pharmacia, Uppsala, Sweden), α32P dTTP (Amersham,
Little Chalfont, UK), 0.05% NP40 in H2O). After incubating for
90 min at 37 °C, 5 μl of the reactions were dotted onto Whatman
filter (Schleicher and Schuell, Dassel, Germany), the filters
washed in 2× SSC buffer and the radioactive signals quantified
using a phosphor imager machine.
Entry assays
To determine entry in 293T cells that overexpress CD4 and
various coreceptors, cells were transiently cotransfected with
5 μg (each) of CD4 and appropriate coreceptor expression
vector. The generation of the CCR2B/CCR5 chimeras has been
described previously (Rucker et al., 1996). In brief, fragments
containing the receptor N-termini and the three extracellular
loops were exchanged between CCR5 and CCR2b employing
appropriate internal restriction sites (Rucker et al., 1996). The
identity of the chimeric receptors was verified by sequence
analysis. After overnight incubation, cells were seeded in 48-
well plates, maintained for 24 h and infected with p27-antigennormalized SIV variants encoding luciferase or enhanced green
fluorescent protein (eGFP) instead of nef. Three days after
inoculation of target cells, infection efficiency was quantified by
luciferase assay or flow cytometry.
Fusion assay
In order to quantify cell to cell fusion driven by the SIV Env
variants analyzed, QT6 effector cells were infected with
vaccinia vTF1.1 encoding T7-polymerase (Alexander et al.,
1992) and transfected with Env-encoding plasmids, while QT6
target cells were transfected with CD4- and coreceptor-
encoding plasmids and a reporter plasmid encoding luciferase
under the control of the T7-promoter. Subsequently, effector
and target cells were mixed and fusion quantified for 7 h after
cocultivation. A detailed description of the fusion assay has
been published previously (Rucker et al., 1997).
Inhibition by TAK-779
Inhibition of viral entry by TAK-779 was investigated by
infection of target cells with replication competent EGFP
reporter viruses. Cells were seeded in 48-well dishes, incubated
in culture medium containing the indicated concentrations of
inhibitor for 1 h and infected with equal volumes of viral
supernatant normalized for comparable infection of target cells
in the absence of inhibitor, as determined by flow cytometry.
Three days after infection cells were harvested and the
percentage of GFP positive cells was assessed by flow
cytometry analysis. Infection of Magi reporter cells was
quantified by determining β-galactosidase activity in cell
lysates employing a commercially available kit according to
the manufacturers instructions (Applied Biosystems, CA,
USA).
Animal studies
Six rhesus macaques of Indian origin were infected by
intravenous inoculation of medium containing 5 ng p27 antigen
of SIVmac 239DL produced by transfected 293T cells. Animals
were housed at the German Primate Center in Göttingen in
accordance with institutional guidelines. The animals were
healthy and seronegative for SIV, D-type retroviruses and
STLV-1 at the time of infection. Blood was collected at regular
intervals and serological, virological and immunological
analysis was performed as described previously (Lang et al.,
1997).
Phenotypic analysis of colonic mononuclear cells by flow
cytometry
Colonic mononuclear cells were isolated from biopsies as
previously described (Kewenig et al., 1999). Triple color
labeling of colonic intestinal lymphocytes was performed
using PE, FITC and Cy 5 conjugated cross-reactive mouse
anti-human mAbs to CD2, CD4, CD8, CD25, CD29, CD69,
HLA-DR (DAKO, Denmark) and CD38 (Ortho Clinical
284 S. Pöhlmann et al. / Virology 360 (2007) 275–285Diagnostics, Neckargemünd, Germany). Labeling was per-
formed as described previously (Kewenig et al., 1999) using
1×105 cells per triple staining. Labeled cells were directly
analyzed by flow cytometry (FACS-Scan, Becton Dickinson,
Mountain View, CA).
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